Tango Therapeutics | 8-K: FY2026 Q2 Revenue Meets Estimate at USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0, meeting the estimate of USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.37, missing the estimate of USD -0.3211.

EBIT: As of FY2026 Q2, the actual value is USD -55.34 M.

Financial Position and Cash Flow

As of June 30, 2026, Tango Therapeutics, Inc. held $1.0 billion in cash, cash equivalents, and marketable securities, which is expected to fund its current operating plan. Cash and cash equivalents were $345.6 million as of June 30, 2026, an increase from $112.3 million as of December 31, 2025. Marketable securities increased to $668.4 million as of June 30, 2026, from $230.9 million as of December 31, 2025. Total current assets stood at $1,031.7 million as of June 30, 2026, compared to $353.8 million as of December 31, 2025. Total liabilities decreased to $49.3 million as of June 30, 2026, from $52.5 million as of December 31, 2025. Total stockholders’ equity significantly increased to $1,024.5 million as of June 30, 2026, from $346.2 million as of December 31, 2025.

Segment Revenue

Collaboration revenue for the three months ended June 30, 2026, was $0, a decrease from $3.2 million for the same period in 2025. For the six months ended June 30, 2026, collaboration revenue was $0, down from $8.6 million for the same period in 2025. This change was primarily due to the recognition of all remaining deferred revenue from the Gilead collaboration in 2025, following the truncation of the agreement.

Operational Metrics (Expenses and Profitability)

Research and Development Expenses

Research and development expenses increased to $37.2 million for the three months ended June 30, 2026, from $32.8 million for the same period in 2025. For the six months ended June 30, 2026, these expenses were $70.7 million, compared to $69.2 million for the same period in 2025. The increase was mainly driven by the advancement of the vopimetostat and TNG456 clinical programs, partially offset by portfolio prioritization efforts.

General and Administrative Expenses

General and administrative expenses rose to $22.6 million for the three months ended June 30, 2026, from $11.3 million for the same period in 2025. For the six months ended June 30, 2026, these expenses were $37.8 million, up from $22.8 million for the same period in 2025. This increase was primarily due to higher personnel-related costs, including share-based compensation.

Total Operating Expenses

Total operating expenses were $59.8 million for the three months ended June 30, 2026, compared to $44.1 million for the same period in 2025. For the six months ended June 30, 2026, total operating expenses reached $108.6 million, an increase from $92.1 million in the prior year period.

Loss from Operations

Loss from operations was - $59.8 million for the three months ended June 30, 2026, compared to - $41.0 million for the same period in 2025. For the six months ended June 30, 2026, loss from operations was - $108.6 million, compared to - $83.5 million for the same period in 2025.

Other Income, Net

Other income, net, increased to $4.4 million for the three months ended June 30, 2026, from $2.1 million for the same period in 2025. For the six months ended June 30, 2026, other income, net, was $7.7 million, up from $4.8 million for the same period in 2025.

Net Loss

Net loss for the three months ended June 30, 2026, was - $55.3 million, compared to a net loss of - $38.9 million for the same period in 2025. For the six months ended June 30, 2026, the net loss was - $100.9 million, compared to - $78.7 million for the same period in 2025.

Unique Metrics (Clinical Data)

Initial Phase ¹⁄₂ data for vopimetostat in combination with daraxonrasib showed a 92% objective response rate and a 90% six-month progression-free survival rate in patients with MTAP-deleted, RAS-mutant pancreatic cancer, with a generally well-tolerated safety profile.

Outlook / Guidance

Tango Therapeutics, Inc. plans to present Phase ¹⁄₂ data of vopimetostat in combination with RAS(ON) inhibitors at the 2026 ESMO Congress and finalize the design of a Phase 3 randomized-controlled trial for front-line pancreatic cancer in the second half of 2026. The company also expects to disclose vopimetostat lung cancer monotherapy data and initial TNG456 data in glioblastoma and other cancers, and initiate a Phase ¹⁄₂ vopimetostat + ERAS-0015 combination study, all in the second half of 2026.